759 related articles for article (PubMed ID: 27062340)
21. Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers.
Rockova V; Abbas S; Wouters BJ; Erpelinck CA; Beverloo HB; Delwel R; van Putten WL; Löwenberg B; Valk PJ
Blood; 2011 Jul; 118(4):1069-76. PubMed ID: 21596848
[TBL] [Abstract][Full Text] [Related]
22. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H
Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
[TBL] [Abstract][Full Text] [Related]
23. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
24. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
[TBL] [Abstract][Full Text] [Related]
25. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
[TBL] [Abstract][Full Text] [Related]
26. High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.
Kao HW; Liang DC; Kuo MC; Wu JH; Dunn P; Wang PN; Lin TL; Shih YS; Liang ST; Lin TH; Lai CY; Lin CH; Shih LY
Oncotarget; 2015 Oct; 6(32):33217-25. PubMed ID: 26375248
[TBL] [Abstract][Full Text] [Related]
27. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
28. DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia.
Sehgal AR; Gimotty PA; Zhao J; Hsu JM; Daber R; Morrissette JD; Luger S; Loren AW; Carroll M
Clin Cancer Res; 2015 Apr; 21(7):1614-20. PubMed ID: 25609058
[TBL] [Abstract][Full Text] [Related]
29. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
[TBL] [Abstract][Full Text] [Related]
30. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J;
Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590
[TBL] [Abstract][Full Text] [Related]
31. A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia.
Sloan CE; Luskin MR; Boccuti AM; Sehgal AR; Zhao J; Daber RD; Morrissette JJ; Luger SM; Bagg A; Gimotty PA; Carroll M
PLoS One; 2016; 11(4):e0153016. PubMed ID: 27050425
[TBL] [Abstract][Full Text] [Related]
32. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia.
Pastore F; Dufour A; Benthaus T; Metzeler KH; Maharry KS; Schneider S; Ksienzyk B; Mellert G; Zellmeier E; Kakadia PM; Unterhalt M; Feuring-Buske M; Buske C; Braess J; Sauerland MC; Heinecke A; Krug U; Berdel WE; Buechner T; Woermann B; Hiddemann W; Bohlander SK; Marcucci G; Spiekermann K; Bloomfield CD; Hoster E
J Clin Oncol; 2014 May; 32(15):1586-94. PubMed ID: 24711548
[TBL] [Abstract][Full Text] [Related]
33. GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia.
Tien FM; Hou HA; Tsai CH; Tang JL; Chiu YC; Chen CY; Kuo YY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Lin CT; Wu SJ; Ko BS; Hsu SC; Huang SY; Yao M; Chou WC; Tien HF
Blood Cancer J; 2018 Aug; 8(9):87. PubMed ID: 30190467
[TBL] [Abstract][Full Text] [Related]
34. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
Dufour A; Schneider F; Hoster E; Benthaus T; Ksienzyk B; Schneider S; Kakadia PM; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Subklewe M; Hiddemann W; Bohlander SK; Spiekermann K;
Ann Hematol; 2012 Jul; 91(7):1051-63. PubMed ID: 22362118
[TBL] [Abstract][Full Text] [Related]
35. Mutational spectrum and associations with clinical features in patients with acute myeloid leukaemia based on next‑generation sequencing.
Li Y; Lv X; Ge X; Yuan D; Ding M; Zhen C; Zhao W; Liu X; Wang X; Xu H; Li Y; Wang X
Mol Med Rep; 2019 May; 19(5):4147-4158. PubMed ID: 30942411
[TBL] [Abstract][Full Text] [Related]
36. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.
Hou HA; Kuo YY; Liu CY; Chou WC; Lee MC; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Blood; 2012 Jan; 119(2):559-68. PubMed ID: 22077061
[TBL] [Abstract][Full Text] [Related]
37. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
[TBL] [Abstract][Full Text] [Related]
38. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD;
J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018
[TBL] [Abstract][Full Text] [Related]
39. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
Schneider F; Hoster E; Schneider S; Dufour A; Benthaus T; Kakadia PM; Bohlander SK; Braess J; Heinecke A; Sauerland MC; Berdel WE; Buechner T; Woermann BJ; Feuring-Buske M; Buske C; Creutzig U; Thiede C; Zwaan MC; van den Heuvel-Eibrink MM; Reinhardt D; Hiddemann W; Spiekermann K
Ann Hematol; 2012 Jan; 91(1):9-18. PubMed ID: 21744003
[TBL] [Abstract][Full Text] [Related]
40. Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia.
Shiba N; Yoshida K; Shiraishi Y; Okuno Y; Yamato G; Hara Y; Nagata Y; Chiba K; Tanaka H; Terui K; Kato M; Park MJ; Ohki K; Shimada A; Takita J; Tomizawa D; Kudo K; Arakawa H; Adachi S; Taga T; Tawa A; Ito E; Horibe K; Sanada M; Miyano S; Ogawa S; Hayashi Y
Br J Haematol; 2016 Nov; 175(3):476-489. PubMed ID: 27470916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
